Back to top
more

Dentsply Sirona (XRAY)

(Delayed Data from NSDQ)

$13.68 USD

13.68
5,583,885

-0.37 (-2.63%)

Updated Aug 6, 2025 04:00 PM ET

After-Market: $13.66 -0.02 (-0.15%) 5:32 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value B Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 24% (60 out of 246)

Industry: Medical - Dental Supplies

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Here's Why You Should Retain Cardinal Health Stock for Now

by Zacks Equity Research

Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment. However, integration risks remain a concern.

Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. CNMD: Which Stock Is the Better Value Option?

Mark Vickery headshot

Top Analyst Reports for Intel, Adobe & Mondelez

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Intel (INTC), Adobe Systems (ADBE) and Mondelez International (MDLZ).

Zacks Equity Research

Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day

by Zacks Equity Research

Paylocity, Macy's, Henry Schein, DENTSPLY and Patterson Companies highlighted as Zacks Bull and Bear of the Day

Sriparna Ghosal headshot

3 Best Dental Stocks to Keep An Eye On

by Sriparna Ghosal

Dental practice management software helps dental businesses run smoothly by ensuring safe storage and easy access of critical information.

Zacks Equity Research

Dentsply (XRAY) Down 2.3% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Dentsply (XRAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Zacks Equity Research

XRAY or COO: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Zacks Equity Research

Allscripts' (MDRX) Veradigm Collaborates With Komodo Health

by Zacks Equity Research

Allscripts (MDRX) expects its Veradigm business to drive bookings in 2019.

Zacks Equity Research

Tandem Diabetes Rides on t:slim X2 Uptake, Product Pipeline

by Zacks Equity Research

Robust domestic sales along with a strong unveiling of the t:slim X2 Insulin Pump in the international markets augur well for Tandem Diabetes (TNDM).

Zacks Equity Research

FDA OKs Medtronic's Evolut TAVR New Indication for Low Risk

by Zacks Equity Research

With the FDA's expanded indication nod, Medtronic's (MDT) Evolut TAVR platform now comes in handy for treating symptomatic severe aortic stenosis patients across all risk categories.

Zacks Equity Research

Here's Why You Should Add Stryker (SYK) to Your Portfolio

by Zacks Equity Research

Stryker (SYK) gains from core segments in the second quarter of 2019.

Zacks Equity Research

Here's Why You Should Hold Varian Medical (VAR) Stock Now

by Zacks Equity Research

Varian (VAR) raises the revenue guidance for fiscal 2019.

Zacks Equity Research

Here's Why You Should Snap Up Baxter International (BAX) Now

by Zacks Equity Research

For 2019, Baxter (BAX) expects adjusted earnings per share within $3.34-$3.40.

Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

by Zacks Equity Research

XRAY vs. COO: Which Stock Is the Better Value Option?

Zacks Equity Research

Stock Market News For Aug 5, 2019

by Zacks Equity Research

Benchmarks closed in the red on Friday to post their worst single-day decline in a month.

Zacks Equity Research

Stock Market News for Aug 02, 2019

by Zacks Equity Research

Benchmarks closed lower on Thursday after President Trump announced plans to impose additional tariffs on imports from China.

Zacks Equity Research

DENTSPLY SIRONA (XRAY) Q2 Earnings Beat, Revenues Fall Y/Y

by Zacks Equity Research

DENTSPLY SIRONA (XRAY) raises guidance for 2019 adjusted EPS.

Zacks Equity Research

Dentsply International (XRAY) Q2 Earnings Top Estimates

by Zacks Equity Research

Dentsply (XRAY) delivered earnings and revenue surprises of 6.45% and -2.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

Zacks Equity Research

Why Earnings Season Could Be Great for Dentsply Sirona (XRAY)

by Zacks Equity Research

Dentsply Sirona (XRAY) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

Zacks Equity Research

Can BD Medical Drive Becton, Dickinson's (BDX) Q3 Earnings?

by Zacks Equity Research

Becton, Dickinson (BDX) expects to gain from core segmental strength in the third quarter.

Zacks Equity Research

Will Genetic Testing Drive Invitae's (NVTA) Q2 Earnings?

by Zacks Equity Research

Invitae (NVTA) expects to deliver a strong second quarter, banking on solid performance of its genetic testing business.

Zacks Equity Research

Illumina (ILMN) Q2 Earnings Beat Estimates, Margins Contract

by Zacks Equity Research

Illumina's (ILMN) witnessed top-line growth across its high and low throughput categories in the second quarter of 2019.

Zacks Equity Research

Why Dentsply (XRAY) Could Beat Earnings Estimates Again

by Zacks Equity Research

Dentsply (XRAY) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Zacks Equity Research

What's in the Cards for DaVita (DVA) This Earnings Season?

by Zacks Equity Research

DaVita (DVA) projects operating income within $460-$465 million for the second quarter.

Zacks Equity Research

GNC Holdings (GNC) Q2 Earnings Beat Estimates, Margins Expand

by Zacks Equity Research

GNC Holdings' (GNC) Q2 revenues decline year over year at each of the three operating segments.